Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
256
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

128
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
128
Gastric Emptying01:16

Gastric Emptying

1.4K
Gastric emptying occurs when the stomach gradually releases chyme into the duodenum. When the stomach is distended, it triggers the release of gastrin, a hormone that promotes gastric acid secretion to aid in digestion. Additionally, stomach distension contributes to peristaltic waves that propel gastric contents toward the pyloric region. The gastroenteric reflex, on the other hand, primarily stimulates peristalsis in the intestines, facilitating the movement of contents further along the...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A nationwide retrospective study of the July effect on nonvariceal upper GI bleeding outcomes in teaching hospitals in the United States.

BMC gastroenterology·2026
Same author

An Unusual Case of Pancreatic Ductal Adenocarcinoma With Synchronous Rectal Metastasis in a Younger Female.

Case reports in gastrointestinal medicine·2026
Same author

Barriers, motivations, and understanding: A qualitative study on the acceptability of an academic weight management program.

PloS one·2026
Same author

Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database.

Proceedings (Baylor University. Medical Center)·2026
Same author

Metastatic Crohn Disease Manifesting as Granulomatous Cheilitis in a Patient With Well-Controlled Crohn Disease.

ACG case reports journal·2026
Same author

Gastric Sarcoidosis Masquerading as Gastroesophageal Reflux Disease: A Case of Diagnostic Uncertainty and Conservative Management.

The American journal of case reports·2026

Related Experiment Video

Updated: Sep 10, 2025

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

23.7K

Alcoholic Use Disorder Outcomes After Roux-en-Y Gastric Bypass in Patients Taking GLP-1 RAs: A Multicenter Analysis.

Olanrewaju Adeniran1, Luis M Nieto2, Chima Amadi3

  • 1Division of Internal Medicine, West Virginia University School of Medicine, Morgantown, West Virginia, USA.

Obesity (Silver Spring, Md.)
|August 26, 2025
PubMed
Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce alcohol use disorders and mortality in patients after Roux-en-Y gastric bypass (RYGB). This study found lower rates of AUD and all-cause mortality in GLP-1 RA users post-RYGB.

Keywords:
Roux‐en‐Y gastric bypassalcohol liver diseasealcohol use disorderglucagon‐like‐peptide‐1 receptor agonists

More Related Videos

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
11:58

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

Published on: August 21, 2021

5.5K
One-anastomosis Gastric Bypass OAGB in Rats
08:16

One-anastomosis Gastric Bypass OAGB in Rats

Published on: November 10, 2018

11.0K

Related Experiment Videos

Last Updated: Sep 10, 2025

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

23.7K
A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
11:58

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

Published on: August 21, 2021

5.5K
One-anastomosis Gastric Bypass OAGB in Rats
08:16

One-anastomosis Gastric Bypass OAGB in Rats

Published on: November 10, 2018

11.0K

Area of Science:

  • Metabolic and Bariatric Surgery
  • Pharmacology
  • Gastroenterology

Background:

  • Roux-en-Y gastric bypass (RYGB) is associated with increased alcohol-related outcomes.
  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in mitigating these risks.

Purpose of the Study:

  • To investigate the impact of GLP-1 RAs on alcohol use outcomes in patients who have undergone RYGB.
  • To compare the incidence of alcohol use disorders (AUD), alcohol liver diseases (ALD), and all-cause mortality between GLP-1 RA users and non-users post-RYGB.

Main Methods:

  • A multicenter retrospective cohort study using TriNetX identified adults with obesity (BMI ≥ 30 kg/m²) who underwent RYGB.
  • Propensity score matching (PSM) balanced covariates between GLP-1 RA initiators and non-users.
  • Outcomes, including AUD, ALD, and all-cause mortality, were assessed over at least 1 year post-RYGB and GLP-1 RA initiation using Cox regression.

Main Results:

  • After PSM, 3438 patients were analyzed in each cohort.
  • GLP-1 RA initiation was linked to a reduced incidence of AUD (1.1% vs. 1.8%; HR 0.77) and all-cause mortality (1.2% vs. 3.9%; HR 0.497).

Conclusions:

  • GLP-1 RAs demonstrate potential in reducing alcohol use disorders post-RYGB.
  • GLP-1 RA use may also decrease all-cause mortality in patients following RYGB surgery.